Anemia is a frequent complication of chronic renal failure (CRF). Insufficient production of glycoprotein hormone erythropoietin (Epo) is a main causative factor of uremic anemia. Currently, regular ...
The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...
Shown is the monthly plasma concentration of erythropoietin (Panel A) and hemoglobin (Panel B) after TARGT EPO implantation in 9 of the 10 patients (the erythropoietin concentration in Patient 7 ...
Please provide your email address to receive an email when new articles are posted on . There are currently four FDA (Food and Drug Administration) approved erythropoiesis stimulating agents (ESAs) ...
Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...
MISGAV, Israel and LONDON, Feb. 3 /PRNewswire/ -- Medgenics (AIM: MEDU/MEDG), today announced that the EPODURE Biopump, the Company's unique tissue-based technology, has successfully demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results